China Shineway adds 9 oral-type Chinese medicines to its product portfolios
Oct 13, 2017

(Hong Kong, 12 October 2017) -- The largest Chinese medicine injections, soft capsules and granules manufacturer in PRC, China Shineway Pharmaceutical Group Limited, and collectively with its subsidiaries ("China Shineway") (SEHK stock code: 2877) told investors in a monthly newsflash the following:

1. Production permits of nine oral-type products acquired by China Shineway are about to complete their transfers. Among them include five National Reimbursement Drug List oral-type Chinese medicines for treating gynaecological diseases (one of them is an exclusive product), and an exclusive oral-type Chinese medicine for treating cardiovascular disease. Upon the transfers, they will be available to enter the market to further enrich China Shineway's product portfolios.

2. SLT Capsule, a multi-components Chinese medicine new drug of China Shineway currently undergoing Phase III clinical trials both in China and Australia for treating vascular dementia, is selected as a Thirteen-Five National Science and Technology Major Project of 2017 and will be entitled for financial grant. Vascular dementia is the second most common cause of dementia following Alzheimer's disease. Currently, no drug can provide effective cure for vascular dementia. Drugs commonly used in clinical therapy are only for slowing down the progression of the disease to reduce functional degradation. Upon succeeding in the development, SLT Capsule will perhaps be the first Chinese medicine new drug registered outside of China

3. The Ministry of Industry and Information has recently announced a list of first batch of green demonstration manufacturers. A total of 203 selected enterprises, including China Shineway among 13 pharmaceutical manufacturers, are listed. The selected enterprises would receive key support from relevant national and local policies. The inclusion to the country's first batch of green demonstration manufacturers reveals China Shineway's emphasis on sustainable supply chain management strategies and its practices.

About China Shineway Pharmaceutical Group Limited (Stock Code: 2877)

China Shineway Pharmaceutical Group Limited is one of the largest modern Chinese medicines manufacturers in the PRC. The Group is listed on the Main Board of Hong Kong Stock Exchange and is also a Hang Seng Composite Index constituent.

Media Contact:

China Shineway Pharmaceutical Group Limited
Mr. Randy Hung │ Tel: (852) 3521-0816 │


- ASIA TODAY News Global Distribution